Los Angeles, USA, March 16, 2021 (GLOBE NEWSWIRE) -- Cholangiocarcinoma Pipeline Insight: Therapeutic analysis of 70+ pipeline therapies and 70+ pharmaceutical companies
Cholangiocarcinoma Pipeline is majorly witnessing TAS-120, AG-120, E7090, and E7090 as the most anticipating therapies.
DelveInsight’s ‘Cholangiocarcinoma (CCA) Pipeline Insights’ report provides a comprehensive portfolio of pipeline therapies and key pharmaceutical companies actively engaged in the domain.
The report lays down complete information on the drug profiles, stages of their clinical development, MoA, RoA, molecule type, and drug delivery platform. Besides, the report proffers a view on
Some of the crucial takeaways from the Cholangiocarcinoma Pipeline report:
- The Cholangiocarcinoma pipeline comprises TT-00420 (TransThera Biosciences), and STP-705 (Sirnaomics) in Phase I clinical stage of development, while CX-4945 (Senhwa Biosciences) and MIV-818 (Medivir) are in Phase I/II stage.
- In mid-stage of development of Cholangiocarcinoma pipeline therapies comprises HMPL-453 (Hutchison Medipharma) and E7090 (Eisai) are in Phase II with Bintrafusp alfa (EMD Serono) in Phase II/III stage of clinical trials.
- AG-120 (Agios Pharmaceuticals) and TAS-120 (Taiho Oncology) are in the late-stage of Cholangiocarcinoma pipeline.
- Key companies dedicated to advance the Cholangiocarcinoma drug pipeline are: Medivir, Hutchison Medipharma, Agios Pharmaceuticals, TransThera Biosciences, Senhwa Biosciences, Eisai, EMD Serono, Taiho Oncology, Sirnaomics, RedHill Biopharma, MacroGenics, Chia Tai Tianqing Pharmaceutical Group, Sirtex Medical, Delcath Systems Inc. Innovent Biologics, PCI Biotech AS, Basilea Pharmaceutica, QED Therapeutics, Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Toray Industries, Bold Therapeutics and several others.
- On March 1, 2021, Agios Pharmaceuticals submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Ivosidenib tablets (AG-120) as a potential treatment for patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma.
- In May 2020, Bold Therapeutics entered into an option agreement with an Hana Pharm Co Ltd for exclusive rights to BOLD 100 in South Korea. Under the terms of the agreement, Bold Therapeutics and Hana Pharm will collaborate for a planned phase Ib/IIa adaptive trial in gastric, pancreatic, colorectal and bile duct (cholangiocarinoma) cancer.
Visit for holistic view @ Cholangiocarcinoma Drug Pipeline
Cholangiocarcinoma is cancer that arises from the cells lining the bile duct, a drainage system for the bile that is produced by the liver. This condition, also known as bile duct cancer, is an uncommon form of cancer that occurs mostly in people older than age 50, though it can occur at any age. Cholangiocarcinomas are part of the family of tumors known as adenocarcinomas, which originate in glandular tissue. Less commonly, they’re squamous cell carcinomas, which develop in the squamous cells that line the digestive tract.
Cholangiocarcinoma Drug Profiles
HMPL-453: Hutchison Medipharma Limited
HMPL‑453 is a novel, highly selective, and potent small-molecule inhibitor that targets FGFR 1, 2, and 3. Hutchison China MediTech Limited (“Chi-Med”) is investigating the therapy in the Phase II stage of development in patients with advanced intrahepatic cholangiocarcinoma (“IHCC”) (NCT04353375).
Cholangiocarcinoma Therapeutic Assessment
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Oral
- Intravenous
- Inhalation
- Subcutaneous
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Parenteral
- Topical
By Molecule Type
- Gene therapy
- Small molecules
- Stem cell therapy
- Gene therapies
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
By Mechanism of Action
- Immunomodulatory
- DNA synthesis inhibitors
- Type 1, 2, 3 fibroblast growth factor receptor antagonist
- Isocitrate dehydrogenase 1 inhibitors
- Sphingosine kinase inhibitors
- Casein kinase II inhibitors
- Type 1, 2, 3, 4 fibroblast growth factor receptor antagonists
- Cyclo-oxygenase 2 inhibitors; RNA interference; Transforming growth factor beta1 inhibitors
- Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants; Programmed cell death-1 ligand-1 inhibitors; Transforming growth factor beta inhibitors
- Aurora kinase A inhibitors; Aurora kinase B inhibitors; Receptor protein-tyrosine kinase antagonists
By Targets
- Protease
- Immunomodulatory
- Multiple kinases
By Stage and Molecule Type
By Stage and Route of Administration
By Stage and Product Type
Key Pipeline Therapies
| Pipeline Therapy | Company | Phase | MoA | RoA |
| MIV-818 | Medivir | I/II | DNA synthesis inhibitors | Oral |
| HMPL-453 | Hutchison Medipharma | II | Type 1 fibroblast growth factor receptor antagonists | Oral |
| BOLD-100 | Bold Therapeutics | I | Apoptosis stimulants; DNA inhibitors; Molecular chaperone GRP78 protein inhibitors | Intravenous |
| TT-00420 | TransThera Biosciences | I | Aurora kinase A inhibitors; Aurora kinase B inhibitors; Receptor protein-tyrosine kinase antagonists | Oral |
| CX-4945 | Senhwa Biosciences | I/II | Casein kinase II inhibitors | Intravenous |
| E7090 | Eisai | II | Type 1, 2, 3 fibroblast growth factor receptor antagonist | Oral |
| Bintrafusp alfa | EMD Serono | II/III | Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants; Programmed cell death-1 ligand-1 inhibitors; Transforming growth factor-beta inhibitors | Intravenous |
| TAS-120 | Taiho Oncology | III | Type 1, 2, 3, 4 fibroblast growth factor receptor antagonists | Oral |
| STP-705 | Sirnaomics | I | Cyclo-oxygenase 2 inhibitors; RNA interference; Transforming growth factor beta1 inhibitors | Intratumoral |
| ABC294640 | RedHill Biopharma | II | Sphingosine kinase inhibitors | Oral |
Know more about the Cholangiocarcinoma Pipeline Therapies and Emerging Trends
Scope of the Report
Coverage: Global
Key Players: Medivir, Hutchison Medipharma, Agios Pharmaceuticals, TransThera Biosciences, Senhwa Biosciences, Eisai, EMD Serono, Taiho Oncology, Sirnaomics, RedHill Biopharma, MacroGenics, Chia Tai Tianqing Pharmaceutical Group, Sirtex Medical, Delcath Systems Inc. Innovent Biologics, PCI Biotech AS, Basilea Pharmaceutica, QED Therapeutics, Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Toray Industries, Bold Therapeutics, and others.
Key Cholangiocarcinoma Pipeline Therapies: MIV-818, HMPL-453, BOLD-100, TT-00420, CX-4945, E7090, Bintrafusp alfa, TAS-120, STP-705, ABC294640, among several others.
Key Questions Answered
- What are the current options for Cholangiocarcinoma treatment?
- How many companies are developing therapies for the treatment of CCA?
- What are the principal therapies developed by these companies in the industry?
- How many Cholangiocarcinoma emerging therapies are in the early-stage, mid-stage, and late stage of development for the treatment of CCA?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the CCA market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of CCA?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing CCA therapies?
- What are the key designations that have been granted for the emerging therapies for Cholangiocarcinoma (CCA)?
Got queries? Get answers @ CCA Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Cholangiocarcinoma Overview |
| 4 | CCA Pipeline Pipeline Therapeutics |
| 5 | Cholangiocarcinoma Pipeline Therapeutic Assessment |
| 6 | CCA – DelveInsight’s Analytical Perspective |
| 7 | In-depth Commercial Cholangiocarcinoma Pipeline Assessment |
| 8 | Cholangiocarcinoma Collaboration Deals |
| 9 | Late Stage CCA Pipeline Products (Phase III and Preregistration) |
| 10 | Mid-Stage Cholangiocarcinoma Pipeline Products (Phase II) |
| 11 | Early-Stage Cholangiocarcinoma Pipeline Products (Phase I) |
| 12 | Pre-clinical and Discovery Stage CCA Pipeline Products |
| 13 | Inactive CCA Pipeline Products |
| 14 | CCA Inactive Products |
| 15 | Cholangiocarcinoma Discontinued Products |
| 16 | Cholangiocarcinoma Dormant Products |
| 17 | Cholangiocarcinoma Key Companies |
| 18 | CCA Key Product Profiles |
| 20 | Cholangiocarcinoma Unmet Needs |
| 21 | CCA Market Drivers and Barriers |
| 22 | CCA Future Perspectives |
| 23 | Cholangiocarcinoma Analyst Views |
| 24 | Cholangiocarcinoma Pipeline Report Methodology |
| 25 | Appendix |
Reach out for a live demo of the report @ Cholangiocarcinoma Emerging Therapies
Related Reports
Cholangiocarcinoma Market
DelveInsight's 'Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast-2028' report.
Intrahepatic Cholangiocarcinoma Market
DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA) - Market Insights, Epidemiology, and Market Forecast–2030’ report.
Nasopharyngeal Neoplasms Market
DelveInsight's "Nasopharyngeal Neoplasms - Market Insights, Epidemiology, and Market Forecast-2030" report.
Natural Killer T Cell Lymphoma Market
DelveInsight's "Natural Killer T Cell Lymphoma (NKTL) - Market Insights, Epidemiology, and Market Forecast-2030" report.
Neoantigen Based Personalized Cancer Therapeutic Vaccines Competitive Landscape
DelveInsight’s ‘Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035’ report.
Nerve Sheath Neoplasms Market
DelveInsight's "Nerve Sheath Neoplasms - Market Insights, Epidemiology, and Market Forecast-2030" report.
Neuroblastoma Market
DelveInsight's "Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2030" report.
Neuroendocrine Carcinoma Market
DelveInsight's "Neuroendocrine Carcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report.
Neurofibroma Market
DelveInsight's "Neurofibroma - Market Insights, Epidemiology, and Market Forecast-2030" report.
Non Hodgkin's Lymphoma Nhl Market
DelveInsight's "Non-Hodgkin's Lymphoma (NHL) - Market Insights, Epidemiology, and Market Forecast-2030" report.
Non Muscle Invasive Bladder Cancer Market
DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report
Non Small Cell Lung Cancer Market
DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030’ report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.